Prevalence and genotype distribution of HPV infection among women in Xiamen, China

Objective This study aimed to evaluate the prevalence of HPV and genotype distribution among female populations in Xiamen, Fujian Province, China, which can be conducive for local governments to formulate cervical cancer screening and HPV vaccine strategies. Methods Cervical swabs were collected from 47,926 participants aged 16–92 years at the Women and Children’s Hospital, Xiamen University, from November 2019 to June 2020. HPV DNA was extracted and detected using conventional PCR, followed by HPV subtype-specific hybridisation. HPV infection rates based on different groups were compared using the χ2 test. HPV prevalence and the corresponding 95% confidence intervals (95% CI) were calculated using SPSS 19.0. Results The overall HPV prevalence among the 47,926 cervical swabs that were analysed was 15.13%, of which single, double, and multiple infections accounted for 76.83, 16.70 and 6.47%, respectively. The age-specific prevalence of HPV infection presented a “U” curve with a HPV prevalence peak observed in women aged <20 years. The gynaecology clinic group had significantly higher HPV positive rates than the health examination group (p < 0.001). The five most common HR-HPV subtypes in Xiamen were HPV52, 58, 16, 51, and 39 (2.69, 1.63, 1.23, 1.05, and 0.98%, respectively). The five most common LR-HPV subtypes were HPV54, 61, 81, 70, 34, and 84 (0.92, 0.86, 0.71, 0.45 and 0.35%, respectively). Conclusion Our findings demonstrate that the 9-valent HPV vaccine is recommended for regular immunisation in Xiamen. It is necessary for elderly women to participate in HPV screening to decrease the morbidity and mortality of cervical cancer.

[1]  Xuewei Zhuang,et al.  HPV prevalence and genotype distribution among women in eastern China during the Covid-19 pandemic , 2023, Human vaccines & immunotherapeutics.

[2]  Chao Zhao,et al.  Immunogenicity, efficacy, and safety of human papillomavirus vaccine: Data from China , 2023, Frontiers in Immunology.

[3]  M. Poljak,et al.  Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis , 2022, The Lancet. Global health.

[4]  Ruili Sun,et al.  Prevalence and distribution of human papillomavirus genotypes among women attending gynecology clinics in northern Henan Province of China , 2022, Virology Journal.

[5]  Hongbo Wang,et al.  Human papillomavirus prevalence and genotype distribution landscapes in Shannan City, Tibet Tibetan Autonomous Region, China , 2021, Virology Journal.

[6]  Yi Huo,et al.  Prevalence and genotype distribution of human papillomavirus infection among women aged 30–65 years in Xi’an, China: a population-based study of 14,655 women , 2021, Human vaccines & immunotherapeutics.

[7]  Yufei Xiao,et al.  Prevalence, characteristics, and distribution of HPV genotypes in women from Zhejiang Province, 2016–2020 , 2021, Virology journal.

[8]  Jie Wu,et al.  Prevalence and Genotype Distribution of Human Papillomavirus Among Healthy Females in Beijing, China, 2016–2019 , 2021, Infection and drug resistance.

[9]  J. Park,et al.  Multiple Human Papilloma Virus (HPV) Infections Are Associated with HSIL and Persistent HPV Infection Status in Korean Patients , 2021, Viruses.

[10]  J. Su,et al.  Prevalence and genotype distribution of high‐risk HPV infection among women in Beijing, China , 2021, Journal of medical virology.

[11]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[12]  Y. Qiao,et al.  Effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screening in China , 2020, JAMA oncology.

[13]  Ying Lu,et al.  Incidence, persistence and clearance of cervical human papillomavirus among women in Guangdong, China 2007-2018: A retrospective cohort study. , 2020, Journal of infection and public health.

[14]  Guosong Shen,et al.  Prevalence and genotype distribution of human papillomavirus infection in Huzhou City, eastern China, 2018-2019. , 2020, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[15]  Zhaoli Zhou,et al.  Characteristics of human papillomavirus infection among women with cervical cytological abnormalities in the Zhoupu District, Shanghai City, China, 2014–2019 , 2020, Virology Journal.

[16]  Y. Huang,et al.  Prevalence of human papillomavirus infection and type distribution among Uyghur females in Xinjiang, northwest China , 2020, Oncology letters.

[17]  J. Zhao,et al.  Comparison of the detection rate of cervical lesion with TruScreen, LBC test and HPV test: A Real-world study based on population screening of cervical cancer in rural areas of China , 2020, PloS one.

[18]  Lanlan Wei,et al.  Epidemiology and persistence of cervical human papillomavirus infection among outpatient women in Heilongjiang province: A retrospective cohort study , 2020, Journal of medical virology.

[19]  Yanfang Jiang,et al.  HPV genotypic spectrum in Jilin province, China, where non-vaccine-covered HPV53 and 51 are prevalent, exhibits a bimodal age-specific pattern , 2020, PloS one.

[20]  Jintao Wang,et al.  Prevalence, genotype distribution and risk factors of cervical HPV infection in Yangqu, China: a population-based survey of 10086 women , 2019, Human vaccines & immunotherapeutics.

[21]  D. Ma,et al.  Human papillomavirus vaccine against cervical cancer: opportunity and challenge. , 2019, Cancer letters.

[22]  T. Zuo,et al.  The prevalence, trends, and geographical distribution of human papillomavirus infection in China: The pooled analysis of 1.7 million women , 2019, Cancer medicine.

[23]  K. Smith-McCune,et al.  Cervical Cancer Screening: More Choices in 2019. , 2019, JAMA.

[24]  A. Burchell,et al.  Human papillomavirus viral load and transmission in young, recently-formed heterosexual couples. , 2019, The Journal of infectious diseases.

[25]  Kemin Li,et al.  The distribution and prevalence of human papillomavirus in women in mainland China , 2019, Cancer.

[26]  Lingbo Jiang,et al.  HPV prevalence and genotype distribution among women in Shandong Province, China: Analysis of 94,489 HPV genotyping results from Shandong’s largest independent pathology laboratory , 2019, PloS one.

[27]  S. Kulasingam,et al.  Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated, HPV-negative women: a modelling study. , 2018, The Lancet. Oncology.

[28]  Y. Meng,et al.  Prevalence characteristics of single and multiple HPV infections in women with cervical cancer and precancerous lesions in Beijing, China , 2018, Journal of medical virology.

[29]  Youzhong Zhang,et al.  Prevalence and Genotype Distribution of Human Papillomavirus in Invasive Cervical Cancer, Cervical Intraepithelial Neoplasia, and Asymptomatic Women in Southeast China , 2018, BioMed research international.

[30]  Ning Wang,et al.  Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. , 2018, The Lancet. Global health.

[31]  Jichun Zhou,et al.  Prevalence of human papillomavirus infection among 71,435 women in Jiangxi Province, China. , 2017, Journal of infection and public health.

[32]  R. Winer,et al.  Natural History of HPV Infection across the Lifespan: Role of Viral Latency , 2017, Viruses.

[33]  Xianjin Zhu,et al.  Epidemiology of Humanpapilloma virus infection among women in Fujian, China , 2017, BMC Public Health.

[34]  Kemin Li,et al.  Human papillomavirus subtypes distribution among 2309 cervical cancer patients in West China , 2017, Oncotarget.

[35]  R. Burk,et al.  Molecular tests potentially improving HPV screening and genotyping for cervical cancer prevention , 2017, Expert review of molecular diagnostics.

[36]  Ruoran Li,et al.  Human papillomavirus vaccine approval in China: a major step forward but challenges ahead. , 2016, The Lancet. Infectious diseases.

[37]  J. Nie,et al.  Multiple human papillomavirus infections and type‐competition in women from a clinic attendee population in China , 2016, Journal of medical virology.

[38]  T. He,et al.  Prevalence and genotype distribution of HPV infection among women in Ningbo, China , 2015, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[39]  Eileen F. Dunne,et al.  HPV and HPV-associated diseases. , 2013, Infectious disease clinics of North America.

[40]  Y. Qiao,et al.  Prevalence of type-specific human papillomavirus and pap results in Chinese women: a multi-center, population-based cross-sectional study , 2013, Cancer Causes & Control.

[41]  Karen Canfell,et al.  The burden of cervical cancer in China: Synthesis of the evidence , 2012, International journal of cancer.

[42]  L. Cai,et al.  Prevalence of genital human papillomavirus infection and genotypes among women from Fujian province, PR China. , 2010, European journal of obstetrics, gynecology, and reproductive biology.

[43]  M. Stanley Pathology and epidemiology of HPV infection in females. , 2010, Gynecologic oncology.

[44]  Vogel Ln Epidemiology of human papilloma virus infection. , 1992, Seminars in dermatology.

[45]  C Milligan,et al.  Screening for cervical cancer. , 1975, The American journal of nursing.